A Phase 4 interventional study of Dotarem and Gadovist in Peripheral Arterial Disease, sponsored by Guerbet. Completed at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-12-11.
Sponsored by Guerbet · Phase 4, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 74 studies in Peripheral Arterial Disease with a site in Austria — 7 open to participants now, 16 under way, 2 of them phase 3. Peripheral Arterial Disease · Austria.
Among the 74 studies in Peripheral Arterial Disease with a site in Austria, this one is the 29th largest by enrollment of the 58 interventional ones that give a count, is the only one that started in 2009, is one of 4 in phase 4, and was the 8th registered.
1,377 studies on the registry are indexed under Peripheral Arterial Disease; 275 are open to participants now.
Browse Peripheral Arterial Disease studies →7 of the 74 studies in Peripheral Arterial Disease with a site in Austria are open now. Recruiting first, the newest first:
Medical University of Graz · Sites in Austria
Ages 18+
Biotronik AG · Sites in Austria, Belgium, France and 5 more countries
Ages 18+
CSL Behring · Sites in Austria, United States, Argentina and 32 more countries
Ages 18+
Medical University Innsbruck · Sites in Austria
Ages 18–99 · Healthy volunteers
Medical University Innsbruck · Sites in Austria
Ages 18+
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 192 Peripheral Arterial Disease studies recruiting now, 138 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
74 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 11 · Phase 4 4
First in 2004; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 189 is above the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 170 across the 58 interventional studies, 376 across the 16 observational. Of the 49 that completed or were terminated, 20 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 74 have an industry lead sponsor. The 10 most frequent:
Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Guerbet has 2 studies filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Peripheral Arterial Disease with a site in Austria that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04110327Micro Medical Solution, Inc.An All-Comers Observational Study of the MicroStent™ Peripheral Vascular Stent System in Subjects With Peripheral Arterial Disease | 2026-12-31 |
| NCT04912323R3 Vascular Inc.Study of the R3 Vascular Drug-Eluting Bioresorbable Scaffold in Treating Below the Knee Arterial Disease | 2026-12-31 |
| NCT07465627Medical University of GrazVessel Recoil in Specific CLTI Populations | 2027-06 |
| NCT05055297M.A. Med Alliance S.A.SELUTION4BTK Trial | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 74 studies in Peripheral Arterial Disease with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is an efficacy evaluation of Dotarem®-enhanced magnetic resonance angiography (MRA) compared to Gadovist®-enhanced MRA in the diagnosis of clinically significant abdominal or lower limb arterial diseases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patient received contrast-enhanced MRA with Gadovist
Drug: Gadovist
Patients received contrast-enhanced MRA with Dotarem
Drug: Dotarem
Intra-patient Accuracy (Percent Agreement), On-site Data
intra-patient accuracy (percent agreement) of each type of MRA examination (Dotarem® or Gadovist®-enhanced MRA) in assessing the lesions of the concerned territory as compared with the gold standard, X-ray angiography.
Time frame: up to one month
Intra-patient Accuracy, in Off-site Readings
• Intra-patient accuracy (percent agreement) of each type of MRA examination (Dotarem® or Gadovist®-enhanced MRA) in assessing the lesions of the concerned territory as compared with the gold standard, X-ray angiography, in off-site readings, using the same methodology as that used for the primary criterion
Time frame: up to one month
Specificity
Specificity of Dotarem® and Gadovist®-enhanced MRA examinations at the segment and the patient levels (gold standard = x-ray angiography) in on-site readings; no stenosis and non significant stenosis were grouped as one class (non significant stenosis = negative segment).
Time frame: up to one month
Sensitivity
sensitivity of Dotarem® and Gadovist®-enhanced MRA examinations at the segment and the patient levels (gold standard = x-ray angiography) in on-site; moderate, severe stenosis and occlusion were grouped as one class (significant stenosis = positive segment).
Time frame: up to one month
Recruitment period between october 2009 and January 2011. Patients were recruited in hospitals.
| Milestone | Gadovist | Dotarem |
|---|---|---|
| Started | 93 | 93 |
| Completed | 88 | 88 |
| Not completed | 5 | 5 |
| Withdrew: Withdrawal by subject | 1 | 3 |
| Withdrew: Change of treatment, patient moved | 4 | 2 |
intra-patient accuracy (percent agreement) of each type of MRA examination (Dotarem® or Gadovist®-enhanced MRA) in assessing the lesions of the concerned territory as compared with the gold standard, X-ray angiography.
| percentage of agreement | Gadovist | Dotarem, Interventional |
|---|---|---|
| Intra-patient Accuracy (Percent Agreement), On-site Data | 77.1 ± 19.6 | 80.6 ± 16.1 |
• Intra-patient accuracy (percent agreement) of each type of MRA examination (Dotarem® or Gadovist®-enhanced MRA) in assessing the lesions of the concerned territory as compared with the gold standard, X-ray angiography, in off-site readings, using the same methodology as that used for the primary criterion
| percentage of agreement | Gadovist | Dotarem, Interventional |
|---|---|---|
| Intra-patient Accuracy, in Off-site Readings | 75.1 ± 15.3 | 73.9 ± 16.7 |
Specificity of Dotarem® and Gadovist®-enhanced MRA examinations at the segment and the patient levels (gold standard = x-ray angiography) in on-site readings; no stenosis and non significant stenosis were grouped as one class (non significant stenosis = negative segment).
| negative segments in MRA | Gadovist | Dotarem, Interventional |
|---|---|---|
| Specificity | 756 | 763 |
sensitivity of Dotarem® and Gadovist®-enhanced MRA examinations at the segment and the patient levels (gold standard = x-ray angiography) in on-site; moderate, severe stenosis and occlusion were grouped as one class (significant stenosis = positive segment).
| positive segment with MRA | Gadovist | Dotarem, Interventional |
|---|---|---|
| Sensitivity | 168 | 191 |
Collected over 15 months in total For each patient, adverse events were collected from signature of inform consent form to the end of the DSA. Non-serious events are listed at a 0.01% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gadovist | — | 0/93 (0%) | 2/92 (2.2%) |
| Dotarem, Interventional | — | 1/93 (1.1%) | 2/92 (2.2%) |
| Event | Gadovist | Dotarem, Interventional |
|---|---|---|
| Acute coronary syndromeCardiac disorders | 0/93 | 1/93 |
| carotid stenosisNervous system disorders | 0/93 | 1/93 |
| Event | Gadovist | Dotarem, Interventional |
|---|---|---|
| FolliculisInfections and infestations | 0/92 | 1/92 |
| contrast extravasationGeneral disorders | 1/92 | 0/92 |
| burningNervous system disorders | 0/92 | 1/92 |
| heat sensation in the faceVascular disorders | 1/92 | 0/92 |
| Age, Categorical(Participants) | Gadovist | Dotarem, Interventional | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 48 | 48 | 96 |
| >=65 years | 45 | 45 | 90 |
| Age Continuous(years) | Gadovist | Dotarem, Interventional | Total |
|---|---|---|---|
| Mean | 66.5 ± 10.2 | 66.8 ± 10.6 | 66.7 ± 10.4 |
| Sex: Female, Male(Participants) | Gadovist | Dotarem, Interventional | Total |
|---|---|---|---|
| Female | 21 | 18 | 39 |
| Male | 72 | 75 | 147 |
| Region of Enrollment(participants) | Gadovist | Dotarem, Interventional | Total |
|---|---|---|---|
| Austria | 19 | 18 | 37 |
| France | 16 | 20 | 36 |
| Germany | 7 | 7 | 14 |
| Italy | 16 | 16 | 32 |
| Spain | 35 | 32 | 67 |
The record gives a start of Oct 2009, a primary completion of Jun 2011 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2012, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gadoterate meglumine